Bortezomib, a proteasome inhibitor for the treatment of multiple myeloma, significantly reduced EZH2 (but not EZH1) in MM.1S myeloma cells and did not affect H3K27Me3 expression 87. The gene discussed is EZH2; the disease is plasma cell myeloma.